Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Heat shock protein 90–Cell division cycle 37 (Hsp90–Cdc37) hetero-chaperone complex is a specialized molecular assembly essential for the maturation and stability of a vast array of protein kinases. Within this complex, Hsp90 serves as the core ATP-dependent chaperone, while Cdc37 acts as a dedicated co-chaperone adaptor that specifically recognizes and recruits kinase clients to the Hsp90 machinery [1, 13, 14]. This interaction is critical for the functional activation of approximately 60% of the human kinome, including key regulators of cell growth and survival such as Akt, Raf-1, and CDK4 [8, 14]. In pathological states like cancer, the complex is often overexpressed or hyperactivated, providing a survival advantage to malignant cells by stabilizing oncogenic kinases [4, 9, 14]. In neurodegenerative diseases, it is implicated in the regulation of kinases that drive toxic protein aggregation [2, 3]. Therapeutic strategies targeting this complex primarily focus on disrupting the protein-protein interaction (PPI) between Hsp90 and Cdc37 using small molecules or natural products like celastrol and withaferin A [2, 14]. Unlike broad-spectrum Hsp90 inhibitors, these PPI disruptors offer a more selective mechanism by specifically targeting kinase-dependent pathways and avoiding the induction of a systemic heat shock response [1, 14, 15]. By preventing the recruitment of kinases to the chaperone, these agents trigger the selective degradation of pathogenic kinases via the ubiquitin-proteasome pathway [1, 14].
Disruption of the protein-protein interaction between Hsp90 and Cdc37, preventing the recruitment and stabilization of client kinases and leading to their ubiquitin-mediated proteasomal degradation [1, 14, 15].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock protein 90–Cell division cycle 37 hetero-chaperone complex (Hsp90–Cdc37 complex).